As a result, gp130 inhibitors (SC144 or bazedoxifene) and a JAK inhibitor (ruxolitinib) were individually investigated at non-cytotoxic doses and resulted in overcoming the acquired IL6-mediated resistance to vincristine in group 3 medulloblastomas [122]. This evidence concerns the gene IL6 and medulloblastoma.